is thanking the Slovenian Research Agency for funding the research through the Core programme Cell Physiology P3 310
In animal reproduction studies, adverse effects on development were observed following intranasal administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity (see Data)
FDA status Neither TB-500 nor BPC-157 is FDA-approved for human therapeutic use
Products designated as Research & Development (R&D) Only are intended exclusively for experimental, analytical, and educational purposes and are not approved as medicines, foods, cosmetics, dietary supplements, or consumer wellness products
Avoid standard oral B12 supplements under 1000 micrograms they fail to correct deficiency in most cases
Swirl or roll gently until fully dissolved dont shake hard